TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05235100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT
Study: NCT03707236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teledermatology visits
Description: Patients in the treatment arm will be taught by study staff how to take the standardized photos of themselves at treatment week 4 (prior to initiation of teledermatology visits). For patients in the treatment arm, the teledermatology visits will be managed by the study staff. A monthly teledermatology visit will consist of sending facial and truncal (if affected) clinical images to a the study staff using Patient Gateway. Once this is completed, the patient and a member of the study staff will have a scheduled telephone appointment during which the provider will screen for any adverse events and will provide counseling as outlined in iPledge guidelines. The patient will also be asked to verbally complete a monthly survey assessing acne severity, quality of life, cost attributable to the appointment, time missed from school/work, satisfaction with treatment. All photographs will be uploaded in LMR/EPIC in the patient's medical record.
Study: NCT05648461

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Five fraction of post operative radiotherapy
Description: Target volume will include tumor bed \& ipsilateral level I-III levels.
Study: NCT05585476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C02 microablative laser
Description: The C02 microablative laser was the first to be used in the treatment of menopausal genitourinary syndrome. Its mechanism of action is based on the emission of light at a wavelength of 10600nm that is absorbed by the water molecules contained in the vaginal mucosa, leading to local remodeling of connective tissue and neoformation of collagen, elastic fibers and other components of the extracellular matrix.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C02 microablative laser
Description: The C02 microablative laser was the first to be used in the treatment of menopausal genitourinary syndrome. Its mechanism of action is based on the emission of light at a wavelength of 10600nm that is absorbed by the water molecules contained in the vaginal mucosa, leading to local remodeling of connective tissue and neoformation of collagen, elastic fibers and other components of the extracellular matrix.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regenerative topical treatment
Description: It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regenerative topical treatment
Description: It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.
Study: NCT05857020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Acupressure
Description: Auricular Acupressure (AA) utilizing all-natural vaccaria ear seeds will be applied to 5 designated sites on each participant's ear (total of 10 seeds placed per patient).~Participants will be asked if they consent to having their ear placement photographed after placement (optional) and audio recorded during interventionist ear seed placement (optional) in collaboration with the BAApress training fidelity study.
Study: NCT05044650

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KOVIR capsule combined with background treatment
Description: KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
Study: NCT05328869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation training
Description: Relaxation training will be performed under the supervision of a physiotherapist. The training is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention will be applied. The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
Study: NCT05487690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printing guide plate
Description: 3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries. to help to reduce intra-operative radiation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional guidance
Description: The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
Study: NCT03903549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]P17-059
Description: Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]P17-059
Description: Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]P17-059
Description: Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning
Study: NCT05639309

Intervention type: DEVICE
Intervention: near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics)
Description: regional oxygen saturation measurement

Intervention type: DEVICE
Intervention: near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics)
Description: regional oxygen saturation measurement
Study: NCT06648837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venepuncture
Description: Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy, additional tubes of blood drawn during normal clinical vist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of relevant information
Description: Collect relevant information to ensure potential participant meets all inclusion/exclusion criteria.
Study: NCT06593938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsule
Description: HRS-5965 capsule for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab Injection
Description: Eculizumab Injection for 24 weeks
Study: NCT06605924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco-free
Description: Ad contains baseline language + language that product is tobacco-free
Study: NCT05801848

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]NaF PET/CT scan
Description: Patients will have their lower back scanned using \[18F\]NaF PET/CT

Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]NaF PET/CT scan
Description: Patients will have their lower back scanned using \[18F\]NaF PET/CT
Study: NCT04900844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGuard Carotid Stent implantation
Description: Implantation of CGuard carotid stent in the eligible patients
Study: NCT06605924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discrete
Description: Ad contains baseline language + language that product is discrete

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convenient
Description: Ad contains baseline language + language that product is convenient
Study: NCT05662124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: Patients will download the patientMpower app and be provided with a spirometer (Spirobank Smart, MIR) and oximeter (Nonin) to record their spirometry and pulse oximetry which will upload to the application via Bluetooth for clinical review.~Patients will be asked to upload measurements three times per week.
Study: NCT05552924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Acupressure
Description: Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
Study: NCT06526598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PMI-targeted pressure support setting and adjustment
Description: During PSV, the pressure support is set and adjusted to a PMI target between 0 and 2 cmH2O.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VT/RR-targeted pressure support setting and adjustment
Description: During PSV, pressure support is set and adjusted according to a VT/RR target of VT between 6 and 8 ml/kg predicted body weight, RR between 20 and 35 breaths/min, and no signs of respiratory distress.
Study: NCT05952297

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sleep Wellness Device (BeCurie)
Description: This device emits micro electromagnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Wellness Device (BeCurie)
Description: This device emits micro electromagnetic stimulation
Study: NCT06700226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AblaView® Unipolar PFA System
Description: Patients with symptomatic paroxysmal atrial fibrillation will be treated with the AblaView® Unipolar PFA System system to achieve electrical isolation of the pulmonary veins. The AblaView® Unipolar PFA Catheter is a regular PFA irrigated catheter. The tip of the catheter has 7 holes distributed around that deliver at the same time irrigation and near infrared light for the OCR system, which will be processed and interpreted by the Console.
Study: NCT06071702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IoNIR Ridaforolimus-Eluting Coronary Stent System
Description: The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloybased stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
Study: NCT05510895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Triplet combination administered neoadjuvant and adjuvant, depending on TRG
Study: NCT05674604

Intervention type: PROCEDURE
Intervention: Cryoneurolysis
Description: This is on observational study. All participants are already candidate for cryoneurolysis. Cryoneurolysis uses a cold probe to generate an ice ball, which initiates Wallerian Degeneration, a process where axon is destroyed but the epineurium and perineurium remain intact. The treated nerve is able to regenerate over time due to this preserved tube.
Study: NCT05836831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.
Study: NCT05253742

Intervention type: OTHER
Intervention: No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner
Description: The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
Study: NCT05042401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703 low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703 high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo high dose
Study: NCT05116397

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspired gas
Description: Inspired gas content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspired gas
Description: Inspired gas content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspired gas
Description: Inspired gas content
Study: NCT06057597

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic OAGB
Description: It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
Study: NCT05419115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQIN-Furosemide
Description: The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8). SC infusion will be performed using the SQIN-Infusor which will deliver 2.7 mL of the SQIN-Furosemide formulation (80mg) over approximately 5 hours, using a biphasic delivery profile.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQIN-Infusor
Description: The investigational device (SQIN-Infusor) is an on-body delivery system that consists of a RU, DU, plus a charger (Figure 2). For the purpose of SUBCUT-HF II trial, the RU will be used for multiple infusions for a single participant. The DU will be used only once per infusion and disposed of. The RU must be charged after each use and will not restart for the next infusion without charging. Charging takes up to 15 minutes. SQIN-Infusor is a bespoke system, adapted from the design of a SC insulin pump. The RU consists of the drive-unit, the controllers, the rechargeable battery, and the user interface.
Study: NCT05754801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunzhi Essence
Description: Yunzhi Essence capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT05671237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bilateral infraorbital+infratrochlear block
Description: we will perform bilateral infraorbital+infratrochlear nerve block
Study: NCT04914871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protocol UN Lifeguard Kids in the Tunja version
Description: The experimental protocol UN Lifeguard Kids in the Tunja version done by the researcher following the guidelines of International organizations such as the American Heart association and European Resuscitation Council.~The intervention consists of 3 sessions of 60 minutes of theoretical and practical exercises on BLS, developed within the usual class schedule.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational session accident prevention and wound management
Description: It will be provided to the control group
Study: NCT05826990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime and enmetazobactam combination
Description: Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
Study: NCT05062551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three steps hysteroscopic resection of an isthmocele
Description: removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
Study: NCT04821960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Mindfulness Program for Fear of Memory Loss
Description: The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Mindfulness Program
Description: Routine non-tailored mindfulness lessons and activities.
Study: NCT04771546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colpofix
Description: Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
Study: NCT05027113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Participants use the meditation app 10% Happier to practice mindfulness meditation (see detailed description in arm/group section)
Study: NCT05826002

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital self-guided psychological intervention for insomnia
Description: A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital self-guided psychological intervention for insomnia
Description: A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital self-guided psychological intervention for insomnia
Description: A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital self-guided psychological intervention for insomnia
Description: A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.
Study: NCT06057597

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic RYGB
Description: A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
Study: NCT05878873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-belt Treadmill
Description: Split-belt treadmill training, where the speed of each leg is controlled independently has been shown to create gait adaptation where the coordination of each leg is altered, creating improved gait symmetry for people with walking impairments.
Study: NCT05791513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using the MAP-Knee Tool
Description: Using the MAP-Knee Tool
Study: NCT05878873

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Split-belt Treadmill
Description: Split-belt treadmill training, where the speed of each leg is controlled independently has been shown to create gait adaptation where the coordination of each leg is altered, creating improved gait symmetry for people with walking impairments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: TENS is a form of nerve stimulation that stimulates at a frequency below motor threshold, targeting activation of sensory receptors, such as muscle spindles. Electrodes that create this stimulation will be placed on the skin superficial to the muscle bellies of the tibialis anterior and rectus femoris.
Study: NCT06504784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber Mixture
Description: 10g/day of dietary fibre mixture - a mixture of oligo-and polysaccharides

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10g/day of placebo (glucose)
Study: NCT05948904

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cryo Ex Vivo
Description: Lungs from patients undergoing lung transplantation after their removal from the recipient patient with previous informed consent signed before transplantation will be obtained. The organs will be placed in an acrylic box and will be kept at a temperature of 37 Celsius degrees. The lungs will be mechanically ventilated connected by an endotracheal tube size 8 inserted in the bronchus with the balloon inflated and a silk suture providing a hermetic closure proximal to the balloon.~Tissue samples will be taken from the models and images will be performed.
Study: NCT05837039

Intervention type: BEHAVIORAL
Intervention: Healthcare Provider
Description: Questionnaires

Intervention type: BEHAVIORAL
Intervention: Caregiver Perception
Description: Questionnaires
Study: NCT05634824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO)
Description: rhTPO at an initial does of 150U/kg qd subcutaneously for 28 days and IVIg 400mg/kg qd for 5 days. The maintenance treatment consisted rhTPO 150U/kg qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin
Description: intravenous immunoglobulin
Study: NCT06513039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin carried on chitosan carrier
Description: Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chitosan carrier
Description: inert scaffold agent
Study: NCT06339086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injection
Description: The subject will receive either a dose of semaglutide subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Injection(Ozempic®)
Description: The subject will receive either a dose of Ozempic® subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.~Treatment duration 32 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.~Treatment duration 32 weeks.
Study: NCT04570878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SC TAP
Description: Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No regional block is provided at the end of surgery.